Gilead Sciences, Inc. (GILD) EV/EBITDA Ratio: 12.91x
Is Gilead Sciences, Inc.’s EV/EBITDA ratio high or low?
Gilead Sciences, Inc.'s EV/EBITDA ratio of 12.91x is 19% below its 5-year average of 15.95x, near the low end of its 5-year range (8.15x–40.48x).
As of Sunday, June 14, 2026. 8.83% below its 12-month average of 14.16x.
GILD EV/EBITDA Ratio Chart
GILD Average EV/EBITDA Ratio Chart
GILD Current vs Average EV/EBITDA Ratio Chart
GILD EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
12.91x
EV/EBITDA RATIO AVG TTM
14.16x
EV/EBITDA RATIO AVG 3Y
17.97x
EV/EBITDA RATIO AVG 5Y
15.95x
EV/EBITDA RATIO AVG 10Y
14.38x
EV/EBITDA RATIO AVG 15Y
14.41x
EV/EBITDA RATIO AVG 20Y
14.79x
CURRENT VS TTM AVG
-8.83%
CURRENT VS 3Y AVG
-28.15%
CURRENT VS 5Y AVG
-19.04%
CURRENT VS 10Y AVG
-10.24%
CURRENT VS 15Y AVG
-10.43%
CURRENT VS 20Y AVG
-12.74%
GILD Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $155.93B | 12.91x | 14.16x | 17.97x | 15.95x |
| Abbott Laboratories (ABT) | $153.59B | 17.30x | 18.75x | 19.31x | 18.59x |
| Pfizer Inc. (PFE) | $149.38B | 12.72x | 10.54x | 15.94x | 13.74x |
| Intuitive Surgical, Inc. (ISRG) | $145.58B | 35.41x | 47.31x | 54.40x | 52.38x |
| Thermo Fisher Scientific Inc. (TMO) | $174.42B | 19.26x | 19.76x | 20.47x | 20.32x |
| CVS Health Corporation (CVS) | $130.09B | 17.90x | 14.94x | 11.88x | 12.01x |
| Danaher Corporation (DHR) | $127.47B | 21.20x | 23.47x | 23.88x | 22.36x |
| Amgen Inc. (AMGN) | $191.70B | 14.29x | 13.59x | 14.31x | 14.03x |
| Bristol-Myers Squibb Company (BMY) | $116.66B | 11.03x | 9.66x | 16.58x | 15.46x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $112.92B | 20.72x | 22.86x | 82.09x | 54.94x |
EV/EBITDA vs. its own history
At 12.9, EV/EBITDA is in its normal range, sitting higher than 50% of its 20-year history.
20-year low
5.1
median
12.9
20-year high
58.0
Gilead Sciences, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The EV/EBITDA ratio for GILD stock is 12.91x.
- Is Gilead Sciences, Inc.'s EV/EBITDA ratio high or low?
- Gilead Sciences, Inc.'s EV/EBITDA ratio of 12.91x is 19% below its 5-year average of 15.95x, near the low end of its 5-year range (8.15x–40.48x).
- What is the TTM average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The TTM average EV/EBITDA ratio for GILD stock is 14.16x.
- What is the 3Y average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The 3Y average EV/EBITDA ratio for GILD stock is 17.97x.
- What is the 5Y average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The 5Y average EV/EBITDA ratio for GILD stock is 15.95x.
- What is the 10Y average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The 10Y average EV/EBITDA ratio for GILD stock is 14.38x.
- What is the 15Y average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The 15Y average EV/EBITDA ratio for GILD stock is 14.41x.
- What is the 20Y average EV/EBITDA ratio for Gilead Sciences, Inc. (GILD)?
- The 20Y average EV/EBITDA ratio for GILD stock is 14.79x.
Gilead Sciences, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-12 | 12.91x |
| 2026-06-11 | 12.93x |
| 2026-06-10 | 12.52x |
| 2026-06-09 | 12.90x |
| 2026-06-08 | 13.14x |
| 2026-06-05 | 13.24x |
| 2026-06-04 | 13.25x |
| 2026-06-03 | 13.23x |
| 2026-06-02 | 13.09x |
| 2026-06-01 | 13.43x |
| 2026-05-29 | 13.74x |
| 2026-05-28 | 13.91x |
| 2026-05-27 | 13.67x |
| 2026-05-26 | 13.67x |
| 2026-05-22 | 13.73x |
| 2026-05-21 | 13.37x |
| 2026-05-20 | 13.39x |
| 2026-05-19 | 13.37x |
| 2026-05-18 | 13.29x |
| 2026-05-15 | 13.28x |
| 2026-05-14 | 13.52x |
| 2026-05-13 | 13.61x |
| 2026-05-12 | 13.79x |
| 2026-05-11 | 13.65x |
| 2026-05-08 | 13.45x |
| 2026-05-07 | 13.70x |
| 2026-05-06 | 13.83x |
| 2026-05-05 | 13.57x |
| 2026-05-04 | 13.49x |
| 2026-05-01 | 13.40x |
| 2026-04-30 | 13.32x |
| 2026-04-29 | 13.14x |
| 2026-04-28 | 13.18x |
| 2026-04-27 | 13.04x |
| 2026-04-24 | 13.28x |
| 2026-04-23 | 13.58x |
| 2026-04-22 | 13.51x |
| 2026-04-21 | 13.55x |
| 2026-04-20 | 13.79x |
| 2026-04-17 | 13.95x |
| 2026-04-16 | 14.04x |
| 2026-04-15 | 14.15x |
| 2026-04-14 | 14.21x |
| 2026-04-13 | 14.08x |
| 2026-04-10 | 14.08x |
| 2026-04-09 | 14.36x |
| 2026-04-08 | 14.31x |
| 2026-04-07 | 14.06x |
| 2026-04-06 | 14.18x |
| 2026-04-02 | 14.14x |
| 2026-04-01 | 14.20x |
| 2026-03-31 | 14.11x |
| 2026-03-30 | 13.83x |
| 2026-03-27 | 13.64x |
| 2026-03-26 | 13.88x |
| 2026-03-25 | 14.01x |
| 2026-03-24 | 13.99x |
| 2026-03-23 | 13.92x |
| 2026-03-20 | 13.91x |
| 2026-03-19 | 14.27x |
| 2026-03-18 | 14.29x |
| 2026-03-17 | 14.58x |
| 2026-03-16 | 14.65x |
| 2026-03-13 | 14.63x |
| 2026-03-12 | 14.65x |
| 2026-03-11 | 14.72x |
| 2026-03-10 | 14.96x |
| 2026-03-09 | 14.78x |
| 2026-03-06 | 14.53x |
| 2026-03-05 | 14.64x |
| 2026-03-04 | 14.93x |
| 2026-03-03 | 14.89x |
| 2026-03-02 | 15.09x |
| 2026-02-27 | 15.00x |
| 2026-02-26 | 14.52x |
| 2026-02-25 | 14.83x |
| 2026-02-24 | 14.87x |
| 2026-02-23 | 15.03x |
| 2026-02-20 | 15.18x |
| 2026-02-19 | 15.15x |
| 2026-02-18 | 15.30x |
| 2026-02-17 | 15.53x |
| 2026-02-13 | 15.50x |
| 2026-02-12 | 15.21x |
| 2026-02-11 | 15.58x |
| 2026-02-10 | 14.79x |
| 2026-02-09 | 15.20x |
| 2026-02-06 | 15.28x |
| 2026-02-05 | 14.99x |
| 2026-02-04 | 14.70x |
| 2026-02-03 | 14.43x |
| 2026-02-02 | 14.40x |
| 2026-01-30 | 14.31x |
| 2026-01-29 | 14.09x |
| 2026-01-28 | 14.10x |
| 2026-01-27 | 14.22x |
| 2026-01-26 | 13.93x |
| 2026-01-23 | 13.76x |
| 2026-01-22 | 13.32x |
| 2026-01-21 | 13.13x |
| 2026-01-20 | 12.68x |
| 2026-01-16 | 12.75x |
| 2026-01-15 | 12.41x |
| 2026-01-14 | 12.67x |
| 2026-01-13 | 12.46x |
| 2026-01-12 | 12.53x |
| 2026-01-09 | 12.40x |
| 2026-01-08 | 12.36x |
| 2026-01-07 | 12.69x |
| 2026-01-06 | 12.42x |
| 2026-01-05 | 12.14x |
| 2026-01-02 | 12.44x |
| 2025-12-31 | 12.55x |
| 2025-12-30 | 12.59x |
| 2025-12-29 | 12.75x |
| 2025-12-26 | 12.73x |
| 2025-12-24 | 12.82x |
| 2025-12-23 | 12.77x |
| 2025-12-22 | 12.68x |
| 2025-12-19 | 12.69x |
| 2025-12-18 | 12.43x |
| 2025-12-17 | 12.42x |
| 2025-12-16 | 12.18x |
| 2025-12-15 | 12.28x |
| 2025-12-12 | 12.33x |
| 2025-12-11 | 12.59x |
| 2025-12-10 | 12.42x |
| 2025-12-09 | 12.24x |
| 2025-12-08 | 12.40x |
| 2025-12-05 | 12.41x |
| 2025-12-04 | 12.54x |
| 2025-12-03 | 12.75x |
| 2025-12-02 | 12.65x |
| 2025-12-01 | 12.69x |
| 2025-11-28 | 12.83x |
| 2025-11-26 | 12.98x |
| 2025-11-25 | 12.95x |
| 2025-11-24 | 12.78x |
| 2025-11-21 | 12.90x |
| 2025-11-20 | 12.75x |
| 2025-11-19 | 13.04x |
| 2025-11-18 | 12.95x |
| 2025-11-17 | 12.67x |
| 2025-11-14 | 12.76x |
| 2025-11-13 | 12.77x |
| 2025-11-12 | 12.61x |
| 2025-11-11 | 12.53x |
| 2025-11-10 | 12.13x |
| 2025-11-07 | 12.19x |
| 2025-11-06 | 15.92x |
| 2025-11-05 | 15.83x |
| 2025-11-04 | 15.87x |
| 2025-11-03 | 15.77x |
| 2025-10-31 | 15.51x |
| 2025-10-30 | 15.35x |
| 2025-10-29 | 15.36x |
| 2025-10-28 | 15.29x |
| 2025-10-27 | 15.58x |
| 2025-10-24 | 15.64x |
| 2025-10-23 | 15.62x |
| 2025-10-22 | 15.70x |
| 2025-10-21 | 16.00x |
| 2025-10-20 | 15.89x |
| 2025-10-17 | 15.85x |
| 2025-10-16 | 15.28x |
| 2025-10-15 | 15.34x |
| 2025-10-14 | 15.36x |
| 2025-10-13 | 15.33x |
| 2025-10-10 | 15.21x |
| 2025-10-09 | 15.16x |
| 2025-10-08 | 15.33x |
| 2025-10-07 | 15.16x |
| 2025-10-06 | 14.80x |
| 2025-10-03 | 14.69x |
| 2025-10-02 | 14.45x |
| 2025-10-01 | 14.52x |
| 2025-09-30 | 14.50x |
| 2025-09-29 | 14.69x |
| 2025-09-26 | 14.63x |
| 2025-09-25 | 14.50x |
| 2025-09-24 | 14.81x |
| 2025-09-23 | 14.89x |
| 2025-09-22 | 14.67x |
| 2025-09-19 | 14.85x |
| 2025-09-18 | 14.80x |
| 2025-09-17 | 14.65x |
| 2025-09-16 | 14.49x |
| 2025-09-15 | 14.68x |
| 2025-09-12 | 14.91x |
| 2025-09-11 | 15.29x |
| 2025-09-10 | 14.99x |
| 2025-09-09 | 15.05x |
| 2025-09-08 | 15.06x |
| 2025-09-05 | 14.96x |
| 2025-09-04 | 14.70x |
| 2025-09-03 | 14.73x |
| 2025-09-02 | 14.70x |
| 2025-08-29 | 14.73x |
| 2025-08-28 | 14.68x |
| 2025-08-27 | 14.84x |
| 2025-08-26 | 14.93x |
| 2025-08-25 | 14.86x |
| 2025-08-22 | 14.93x |
| 2025-08-21 | 15.09x |
| 2025-08-20 | 15.39x |
| 2025-08-19 | 15.30x |
| 2025-08-18 | 15.30x |
| 2025-08-15 | 15.34x |
| 2025-08-14 | 15.42x |
| 2025-08-13 | 15.55x |
| 2025-08-12 | 15.53x |
| 2025-08-11 | 15.58x |
| 2025-08-08 | 15.46x |
| 2025-08-07 | 14.42x |
| 2025-08-06 | 14.73x |
| 2025-08-05 | 14.99x |
| 2025-08-04 | 15.23x |
| 2025-08-01 | 15.07x |
| 2025-07-31 | 14.97x |
| 2025-07-30 | 15.26x |
| 2025-07-29 | 15.20x |
| 2025-07-28 | 15.06x |
| 2025-07-25 | 15.43x |
| 2025-07-24 | 15.08x |
| 2025-07-23 | 15.12x |
| 2025-07-22 | 14.72x |
| 2025-07-21 | 14.49x |
| 2025-07-18 | 14.48x |
| 2025-07-17 | 14.55x |
| 2025-07-16 | 14.68x |
| 2025-07-15 | 14.58x |
| 2025-07-14 | 14.94x |
| 2025-07-11 | 14.65x |
| 2025-07-10 | 15.24x |
| 2025-07-09 | 15.08x |
| 2025-07-08 | 14.82x |
| 2025-07-07 | 14.91x |
| 2025-07-03 | 14.90x |
| 2025-07-02 | 14.88x |
| 2025-07-01 | 14.90x |
| 2025-06-30 | 14.80x |
| 2025-06-27 | 14.78x |
| 2025-06-26 | 14.41x |
| 2025-06-25 | 14.21x |
| 2025-06-24 | 14.36x |
| 2025-06-23 | 14.24x |
| 2025-06-20 | 14.52x |
| 2025-06-18 | 14.46x |
| 2025-06-17 | 14.46x |
| 2025-06-16 | 14.80x |
| 2025-06-13 | 14.69x |
| 2025-06-12 | 14.94x |
| 2025-06-11 | 14.61x |
| 2025-06-10 | 14.71x |
| 2025-06-09 | 15.05x |
| 2025-06-06 | 14.99x |
| 2025-06-05 | 14.75x |
| 2025-06-04 | 14.58x |
| 2025-06-03 | 14.62x |
| 2025-06-02 | 14.57x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day